Purpose To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care
(BSC) including hydroxyurea as first-line therapy in older patients with acute myeloid …

Purpose This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab
ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute …

Purpose There has been little survival improvement in older patients with acute myeloid
leukemia (AML) in the last two decades. Improving induction treatment may improve the rate …

In older patients with acute myeloid leukemia (AML), the prevention of relapse has remained
one of the major therapeutic challenges, with more than 75% relapses after complete …

The treatment of older patients with acute myeloid leukaemia, who are not considered
suitable for conventional intensive therapy, is unsatisfactory. Low-dose Ara-C (LDAC) has …

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of
gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves …

Background Gemtuzumab ozogamicin was the first example of antibody-directed
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …

The therapeutic activity and toxicity profile of gemtuzumab ozogamicin were assessed in 40
patients> 60 years of age with acute myeloid leukemia (AML) who were not considered …

Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit
more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin …

This randomized phase 3 clinical trial evaluated the potential benefit of the addition of
gemtuzumab ozogamicin (GO) to standard induction and postconsolidation therapy in …